Search - tctmd.com

Displaying 41 - 60 of 217

Sort: Relevancy | Date

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

March 08, 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

News Conference News CRT 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

Yael L. Maxwell

February 28, 2023

BP Reduction With Renal Denervation Still Evident a Decade On

News Daily News

BP Reduction With Renal Denervation Still Evident a Decade On

Michael O'Riordan

January 31, 2023

Reduction in BP Drives Treatment Preference for Hypertensive Patients

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

TCTMD’s Top 10 Most Popular Stories for September 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2022

October 03, 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

News Conference News TCT 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

September 18, 2022

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Presentation TCT 2022

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Presenter: Deepak Bhatt

September 18, 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 07, 2022

RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation

News Daily News

RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation

July 26, 2022

Registry Data Hint at MACE Benefit with Renal Denervation

News Conference News EuroPCR 2022

Registry Data Hint at MACE Benefit With Renal Denervation

Michael O'Riordan

May 17, 2022

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

News Conference News ACC 2022

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

April 08, 2022

Renal Denervation a Third Option for Hypertension, European Experts Say

News Daily News

Renal Denervation a Third Option for Hypertension, European Experts Say

September 17, 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

TCT 419: Patients With Resistant Hypertension in the Global SYMPLICITY Registry: Anti-Hypertensive Medication Burden and Changes in Blood Pressure out to 3 Years

Presentation TCT 2020

TCT 419: Patients With Resistant Hypertension in the Global SYMPLICITY Registry: Anti-Hypertensive Medication Burden and Changes in Blood Pressure out to 3 Years

Presenter: Markus Schlaich

October 14, 2020

New Data Add to Resurgent Renal Denervation Field

News Conference News EuroPCR 2020

New Data Add to Resurgent Renal Denervation Field

June 26, 2020

Renal Denervation Lowers BP Across High-risk Groups: Global SYMPLICITY Registry

News Daily News

Renal Denervation Lowers BP Across High-risk Groups: Global SYMPLICITY Registry

June 09, 2020

Renal Denervation Lowers BP in Pivotal SPYRAL HTN-OFF MED Trial

News Conference News ACC 2020

Renal Denervation Lowers BP in Pivotal SPYRAL HTN-OFF MED Trial

March 30, 2020

TCT 82: Long-Term Clinical Outcomes After Renal Denervation in an Asian Population: Results From the Global SYMPLICITY Registry in South Korea (GSR Korea)

Presentation TCT 2019

TCT 82: Long-Term Clinical Outcomes After Renal Denervation in an Asian Population: Results From the Global SYMPLICITY Registry in South Korea (GSR Korea)

Presenter: Byeong-Keuk Kim

September 25, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.